Cowen & Co. Keeps a Buy Rating on Sarepta Therapeutics (SRPT)


In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT), with a price target of $178. The company’s shares opened today at $125.01.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.0% and a 55.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $198.60 average price target, representing a 58.9% upside. In a report issued on August 1, Morgan Stanley also upgraded the stock to Buy with a $163 price target.

.

See today’s analyst top recommended stocks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $109 million. In comparison, last year the company had a GAAP net loss of $63.05 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.

Read More on SRPT:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts